1. Home
  2. SCYX vs NINE Comparison

SCYX vs NINE Comparison

Compare SCYX & NINE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCYX
  • NINE
  • Stock Information
  • Founded
  • SCYX 1999
  • NINE 2011
  • Country
  • SCYX United States
  • NINE United States
  • Employees
  • SCYX N/A
  • NINE N/A
  • Industry
  • SCYX Biotechnology: Pharmaceutical Preparations
  • NINE Oilfield Services/Equipment
  • Sector
  • SCYX Health Care
  • NINE Energy
  • Exchange
  • SCYX Nasdaq
  • NINE Nasdaq
  • Market Cap
  • SCYX 50.3M
  • NINE 38.9M
  • IPO Year
  • SCYX 2014
  • NINE 2018
  • Fundamental
  • Price
  • SCYX $1.02
  • NINE $1.04
  • Analyst Decision
  • SCYX Buy
  • NINE
  • Analyst Count
  • SCYX 1
  • NINE 0
  • Target Price
  • SCYX N/A
  • NINE N/A
  • AVG Volume (30 Days)
  • SCYX 210.1K
  • NINE 955.3K
  • Earning Date
  • SCYX 11-06-2024
  • NINE 10-31-2024
  • Dividend Yield
  • SCYX N/A
  • NINE N/A
  • EPS Growth
  • SCYX N/A
  • NINE N/A
  • EPS
  • SCYX N/A
  • NINE N/A
  • Revenue
  • SCYX $8,566,000.00
  • NINE $556,751,000.00
  • Revenue This Year
  • SCYX N/A
  • NINE N/A
  • Revenue Next Year
  • SCYX $405.82
  • NINE $2.93
  • P/E Ratio
  • SCYX N/A
  • NINE N/A
  • Revenue Growth
  • SCYX N/A
  • NINE N/A
  • 52 Week Low
  • SCYX $0.90
  • NINE $0.75
  • 52 Week High
  • SCYX $3.07
  • NINE $3.26
  • Technical
  • Relative Strength Index (RSI)
  • SCYX 34.82
  • NINE 42.86
  • Support Level
  • SCYX $0.90
  • NINE $0.90
  • Resistance Level
  • SCYX $1.04
  • NINE $1.06
  • Average True Range (ATR)
  • SCYX 0.07
  • NINE 0.11
  • MACD
  • SCYX -0.01
  • NINE -0.03
  • Stochastic Oscillator
  • SCYX 34.10
  • NINE 27.12

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

About NINE Nine Energy Service Inc.

Nine Energy Service Inc is a North American onshore completion and production services provider. It targets unconventional oil and gas resource development. It operates in one segment, Completion Solutions. The Completion Solutions segment offers cementing services; completion tools, including liner hangers and accessories, frac sleeves, fully composite frac plugs, and specialty open hole float equipment and centralizers and other services. It operates in the U.S, Canada, and other countries where majority of the revenue is generated from the United States.

Share on Social Networks: